Luteolytic and antiluteolytic effect of the antiprogestagen RU486 in pseudopregnant rats.
To study the effects of the antiprogestagen RU486 on luteal activity in pseudopregnant rats, adult female rats made pseudopregnant by sterile copulation were given daily injections with oil vehicle or with RU486 (2 mg/day) either during the entire period of pseudopregnancy (day 1 till day 14) or during the second half of pseudopregnancy (day 8 till day 14). Blood was taken every other day to measure serum concentrations of progesterone. At autopsy, on day 15, the weights of ovaries, isolated corpora lutea and pituitary glands were recorded. In a second study using the same experimental protocol, blood was taken via a jugular vein cannula on days 8, 9, 10 and 11 after induction of pseudopregnancy; on each of these days blood samples were taken at 0700, 0800 and 0900 h, and at 1700, 1800 and 1900 h to measure plasma concentrations of prolactin, LH and progesterone. Administration of RU486 from day 1 of pseudopregnancy onwards had no effect on the increasing concentrations of serum progesterone during the first half of pseudopregnancy. Thereafter progesterone concentrations of serum progesterone during the first half of pseudopregnancy. Thereafter progesterone concentrations increased further in RU486-treated rats whereas they decreased in oil-treated pseudopregnant rats. Administration of RU486 from day 8 of pseudopregnancy onwards resulted in a decline in progesterone concentrations in serum on day 10 followed by ovulation on day 11. Plasma LH concentrations in rats treated with RU486 from day 1 of pseudopregnancy were higher than those in oil-treated rats on days 8, 9, 10 and 11.(ABSTRACT TRUNCATED AT 250 WORDS)
Uilenbroek
J T
JT
Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Erasmus University, Rotterdam, The Netherlands.
van der Schoot
P
P
Mattheij
J A
JA
Swarts
J J
JJ
D000818:Animals; D003338:Corpus Luteum / Q000033:anatomy & histology / Q000187:drug effects*; D003340:Corpus Luteum Maintenance / Q000187:drug effects; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D015735:Mifepristone / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000033:anatomy & histology; D010902:Pituitary Gland / Q000033:anatomy & histology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D011555:Pseudopregnancy / Q000097:blood*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D015735:Mifepristone; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone